News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
737,222 Results
Type
Article (63794)
Company Profile (444)
Press Release (672965)
Multimedia
Podcasts (143)
Webinars (22)
Section
Business (194880)
Career Advice (3419)
Deals (35217)
Drug Delivery (132)
Drug Development (85387)
Employer Resources (185)
FDA (17508)
Job Trends (15245)
News (343731)
Policy (35917)
Tag
Academia (2951)
Academic (1)
Accelerated approval (17)
Adcomms (33)
Allergies (116)
Alliances (50580)
ALS (134)
Alzheimer's disease (1631)
Antibody-drug conjugate (ADC) (203)
Approvals (17493)
Artificial intelligence (406)
Autoimmune disease (46)
Automation (23)
Bankruptcy (371)
Best Places to Work (11850)
BIOSECURE Act (22)
Biosimilars (144)
Biotechnology (326)
Bladder cancer (118)
Brain cancer (45)
Breast cancer (429)
Cancer (3471)
Cardiovascular disease (302)
Career advice (2903)
Career pathing (35)
CAR-T (227)
CDC (46)
Cell therapy (615)
Cervical cancer (29)
Clinical research (70312)
Collaboration (1255)
Company closure (4)
Compensation (850)
Complete response letters (50)
COVID-19 (2912)
CRISPR (77)
C-suite (484)
Cystic fibrosis (128)
Data (3674)
Decentralized trials (2)
Denatured (46)
Depression (94)
Diabetes (405)
Diagnostics (6703)
Digital health (28)
Diversity (7)
Diversity, equity & inclusion (47)
Drug discovery (192)
Drug pricing (166)
Drug shortages (36)
Duchenne muscular dystrophy (181)
Earnings (77179)
Editorial (52)
Employer branding (22)
Employer resources (159)
Events (119507)
Executive appointments (923)
FDA (19681)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (11)
Funding (1105)
Gene editing (163)
Generative AI (32)
Gene therapy (488)
GLP-1 (973)
Government (5137)
Grass and pollen (7)
Guidances (327)
Healthcare (19884)
HIV (45)
Huntington's disease (33)
IgA nephropathy (52)
Immunology and inflammation (213)
Immuno-oncology (17)
Indications (45)
Infectious disease (3126)
Inflammatory bowel disease (176)
Inflation Reduction Act (13)
Influenza (85)
Intellectual property (158)
Interviews (663)
IPO (16711)
IRA (59)
Job creations (3811)
Job search strategy (2365)
Kidney cancer (14)
Labor market (64)
Layoffs (606)
Leadership (29)
Legal (8561)
Liver cancer (89)
Longevity (12)
Lung cancer (503)
Lymphoma (249)
Machine learning (20)
Management (62)
Manufacturing (537)
MASH (115)
Medical device (13990)
Medtech (14005)
Mergers & acquisitions (19334)
Metabolic disorders (1044)
Multiple sclerosis (115)
NASH (23)
Neurodegenerative disease (179)
Neuropsychiatric disorders (48)
Neuroscience (2508)
NextGen: Class of 2025 (7042)
Non-profit (4844)
Now hiring (45)
Obesity (532)
Opinion (298)
Ovarian cancer (113)
Pain (151)
Pancreatic cancer (143)
Parkinson's disease (212)
Partnered (23)
Patents (377)
Patient recruitment (258)
Peanut (56)
People (58003)
Pharmaceutical (87)
Pharmacy benefit managers (25)
Phase I (21801)
Phase II (30786)
Phase III (23232)
Pipeline (2405)
Policy (276)
Postmarket research (2895)
Preclinical (9482)
Press Release (69)
Prostate cancer (169)
Psychedelics (49)
Radiopharmaceuticals (279)
Rare diseases (587)
Real estate (6133)
Recruiting (72)
Regulatory (25436)
Reports (49)
Research institute (2630)
Resumes & cover letters (544)
Rett syndrome (11)
RNA editing (15)
RSV (63)
Schizophrenia (117)
Series A (181)
Series B (138)
Service/supplier (13)
Sickle cell disease (75)
Special edition (24)
Spinal muscular atrophy (161)
Sponsored (39)
Startups (3727)
State (2)
Stomach cancer (17)
Supply chain (91)
Tariffs (81)
The Weekly (96)
Vaccines (995)
Venture capital (63)
Weight loss (361)
Women's health (51)
Worklife (21)
Date
Today (98)
Last 7 days (557)
Last 30 days (2534)
Last 365 days (32967)
2025 (22596)
2024 (37012)
2023 (41641)
2022 (52833)
2021 (57445)
2020 (55782)
2019 (48569)
2018 (36862)
2017 (34903)
2016 (34814)
2015 (39967)
2014 (33008)
2013 (27889)
2012 (29738)
2011 (29995)
2010 (28001)
Location
Africa (1027)
Alabama (77)
Alaska (7)
Arizona (251)
Arkansas (14)
Asia (43728)
Australia (7593)
California (8666)
Canada (2630)
China (817)
Colorado (362)
Connecticut (386)
Delaware (226)
Europe (101215)
Florida (1294)
Georgia (291)
Hawaii (3)
Idaho (63)
Illinois (730)
India (41)
Indiana (392)
Iowa (19)
Japan (260)
Kansas (116)
Kentucky (34)
Louisiana (18)
Maine (75)
Maryland (1184)
Massachusetts (6565)
Michigan (276)
Minnesota (513)
Mississippi (3)
Missouri (104)
Montana (29)
Nebraska (21)
Nevada (95)
New Hampshire (75)
New Jersey (2405)
New Mexico (31)
New York (2377)
North Carolina (1292)
North Dakota (10)
Northern California (3903)
Ohio (269)
Oklahoma (18)
Oregon (38)
Pennsylvania (1819)
Puerto Rico (17)
Rhode Island (40)
South America (1397)
South Carolina (44)
South Dakota (1)
Southern California (3300)
Tennessee (135)
Texas (1329)
United States (32028)
Utah (256)
Virginia (218)
Washington D.C. (79)
Washington State (733)
West Virginia (4)
Wisconsin (86)
737,222 Results for "the parkinson s institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Arrowhead Nabs up to $2B Novartis Commitment for siRNA Parkinson’s Program
Novartis is licensing ARO-SNCA, a preclinical siRNA therapy for synucleinopathies, a group of neurodegenerative disorders including Parkinson’s disease.
September 2, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease
September 10, 2025
·
7 min read
Press Releases
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
September 5, 2025
·
8 min read
Press Releases
NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
September 8, 2025
·
6 min read
Press Releases
Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway
August 26, 2025
·
7 min read
Press Releases
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease
July 24, 2025
·
10 min read
Press Releases
Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson’s Disease
August 6, 2025
·
1 min read
Neurodegenerative disease
Inhibikase Scraps Parkinson’s Drug After Disappointing Mid-Stage Data
Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and abandoned assets in recent months.
January 30, 2025
·
2 min read
·
Tristan Manalac
Press Releases
NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor
August 12, 2025
·
5 min read
Press Releases
Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease
August 15, 2025
·
7 min read
1 of 73,723
Next
